Your Strongest Ally to Conquer Cancer

Phone: 505.842.8171

dotAfter Hours: 505.857.3877

dotPharmacy: 505.822.3911

Current NMCC Clinical Trials

RTOG 1205: Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma PENDING IRB approval & Credentialing

Breast Adjuvant
NSABP B-51, RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy Pending Credentialing

SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer OPEN ACTIVE

ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy Pending IRB Approval

Breast Advanced
HER2 +, ER/PR +/+
ECOG E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer OPEN ACTIVE

ECOG E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer OPEN ACTIVE

Cholangio Advanced
SWOG S1310: Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer Temp Closed for Analysis PENDING IRB Submission

Gastric Advanced
Alliance A021202: Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors Temp Closed PENDING IRB Submission

RTOG 0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer PENDING Credentialing

PrTK03: Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer PENDING Contract & IRB Submission

GU Advanced
Hoosier Oncology Group GU12-160: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination with OGX-427 in Patients with Relapsed or Refractory Metastatic Urothelial Carcinoma after Receiving a Platinum-containing Regimen; The Borealis-2 Clinical Trial OPEN ACTIVE

Head & Neck
H&N Adjuvant
RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck PENDING IRB Submission & Credentialing

CALGB 50904: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC #681239, IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma IRB Approval PENDING

Millennium C16014: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagnosed Multiple Myeloma OPEN-ACTIVE

RTOG 1306: A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC) PENDING IRB Submission & Credentialing

Peregrine PPHM 1202: SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab plus Docetaxel versus Docetaxel Alone as Second-Line Therapy in Patients with Stage IIIB/IV Non-Squamous Non Small-Cell Lung Cancer PENDING TRAINING

ECOG E2511: Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer OPEN-ACTIVE

NRG-BR001: A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases (Breast, Prostate, NSCLC with ≥ 4 Mets) PENDING IRB and Credentialing

Novartis Signature
Novartis CBGJ398XUS04: Modular Phase II study to Link Target Therapy to Patients with Pathway Activated Tumors: Module – 6 BGJ398 for Patients with FGFR Altered Tumors (Signature Trial) OPEN-ACTIVE

Novartis CLDK378AUS23: Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1 (Signature Trial) OPEN-ACTIVE

INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives OPEN-ACTIVE